Protalix BioTherapeutics, Inc.
US ˙ NYSEAM ˙ US74365A3095

SecurityPLX / Protalix BioTherapeutics, Inc.
InstitutionWolverine Trading, Llc
Latest Disclosed Ownership70,394 shares
Latest Disclosed Value $ 152,051
Wolverine Trading, Llc ownership in PLX / Protalix BioTherapeutics, Inc.

On November 14, 2025 - Wolverine Trading, Llc filed a 13F-HR form disclosing ownership of 70,394 shares of Protalix BioTherapeutics, Inc. (US:PLX) valued at $156,275 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 18, 2025 disclosing 24,508 shares of Protalix BioTherapeutics, Inc.. This represents a change in shares of 187.23% during the quarter. The current value of the position is $137,972 USD.

Wolverine Trading, Llc has a history of taking positions in derivatives of the underlying security (PLX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 32,800 of underlying shares valued at $70,848 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

PLX / Protalix BioTherapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 70,394 45,886 187.23 152 310.81 0.0001
2025-08-18 2025-06-30 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 24,508 24,508 38 0.0000
2023-11-15 2023-09-30 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 0 -17,208 -100.00 0 -100.00
2023-08-23 2023-06-30 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 17,208 17,208 37 0.0000
2022-02-14 2021-12-31 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 0 -28,168 -100.00 0 -100.00
2021-11-12 2021-09-30 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 28,168 -17,138 -37.83 39 -55.17 0.0000
2021-08-06 2021-06-30 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 45,306 26,508 141.02 87 2.35 0.0001
2021-05-14 2021-03-31 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 18,798 7,920 72.81 85 123.68 0.0001
2021-02-12 2020-12-31 13F PROTALIX BIOTHERAPEUTICS COM 74365A309 10,878 10,878 38 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-08-18 2025-06-30 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F PROTALIX BIOTHERAPEUTICS COM Call 11,700 30 n/a n/a n/a
2024-05-15 2024-03-31 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-14 2023-12-31 13F PROTALIX BIOTHERAPEUTICS COM Call 32,100 57 n/a n/a n/a
2023-11-15 2023-09-30 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-23 2023-06-30 13F PROTALIX BIOTHERAPEUTICS COM Call 141,900 308 n/a n/a n/a
2023-05-15 2023-03-31 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-02-14 2022-12-31 13F PROTALIX BIOTHERAPEUTICS COM Call 13,000 18 n/a n/a n/a
2022-11-14 2022-09-30 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-15 2022-06-30 13F PROTALIX BIOTHERAPEUTICS COM Call 12,000 13 n/a n/a n/a
2022-05-16 2022-03-31 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F PROTALIX BIOTHERAPEUTICS COM Call 22,700 -69.69 19 -81.55 n/a n/a n/a
2021-11-12 2021-09-30 13F PROTALIX BIOTHERAPEUTICS COM Call 74,900 1.49 103 -26.95 n/a n/a n/a
2021-08-06 2021-06-30 13F PROTALIX BIOTHERAPEUTICS COM Call 73,800 290.48 141 65.88 n/a n/a n/a
2021-05-14 2021-03-31 13F PROTALIX BIOTHERAPEUTICS COM Call 18,900 85 n/a n/a n/a
2021-02-12 2020-12-31 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-11-13 2020-09-30 13F PROTALIX BIOTHERAPEUTICS COM Call 11,800 46 n/a n/a n/a
2020-08-13 2020-06-30 13F PROTALIX BIOTHERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-11 2020-03-31 13F PROTALIX BIOTHERAPEUTICS COM Call 23,300 55 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-14 2025-09-30 13F PROTALIX BIOTHERAPEUTICS COM Put 32,800 57.69 71 118.75 n/a n/a n/a
2025-08-18 2025-06-30 13F PROTALIX BIOTHERAPEUTICS COM Put 20,800 32 n/a n/a n/a
2023-11-15 2023-09-30 13F PROTALIX BIOTHERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-23 2023-06-30 13F PROTALIX BIOTHERAPEUTICS COM Put 15,100 33 n/a n/a n/a
2022-05-16 2022-03-31 13F PROTALIX BIOTHERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F PROTALIX BIOTHERAPEUTICS COM Put 10,000 -50.00 9 -66.67 n/a n/a n/a
2021-11-12 2021-09-30 13F PROTALIX BIOTHERAPEUTICS COM Put 20,000 -57.17 27 -69.66 n/a n/a n/a
2021-08-06 2021-06-30 13F PROTALIX BIOTHERAPEUTICS COM Put 46,700 54.64 89 -34.56 n/a n/a n/a
2021-05-14 2021-03-31 13F PROTALIX BIOTHERAPEUTICS COM Put 30,200 136 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.